Immatics (IMTX) Interest Income - Net (2019 - 2026)
Immatics (IMTX) posted Interest Income - Net of -$45.1 million for Q4 2025, down 965.7% sequentially from -$4.2 million in Q3 2025, and down 541.2% YoY from $10.2 million in Q4 2024.
Analysis
Immatics (IMTX) Interest Income - Net (2019 - 2026) Analysis & Trends
Immatics has reported Interest Income - Net for 7 years, with the latest figure at -$45.1 million in Q4 2025.
- Quarterly Interest Income - Net fell 541.2% year-over-year to -$45.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$71.7 million (down 470.39% YoY) and the FY2025 annual result came in at -$60.8 million, down 137.36% from the prior year.
- Interest Income - Net eased to -$45.1 million in Q4 2025 per IMTX's latest filing, from -$4.2 million in the prior quarter.
- Over five years, Interest Income - Net peaked at $8.3 million in Q1 2025 and troughed at -$45.1 million in Q4 2025.
- A 5-year average of -$3.9 million and a median of $12834.9 in 2021 frame the typical range for Interest Income - Net.
- The sharpest annual moves came in 2022 and 2023: Interest Income - Net surged 1248.05% in 2022, then slumped 1563.5% in 2023.
- Over 5 years, Interest Income - Net stood at $337471.4 in 2021, then soared by 1248.05% to $4.5 million in 2022, then sank by 59.36% to $1.8 million in 2023, then slumped by 480.59% to -$7.0 million in 2024, then plunged by 541.2% to -$45.1 million in 2025.
- According to Business Quant data, Interest Income - Net over the past three periods registered -$45.1 million, -$4.2 million, and -$30.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Income - Net (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | -235,959.46 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -235,959.46 |
| Mar 31, 2026 | -248,198.08 |
| Dec 31, 2025 | -258,417.66 |
| Sep 30, 2025 | -270,051.73 |
| Jun 30, 2025 | -276,198.16 |
| Mar 31, 2025 | -261,919.23 |
| Dec 31, 2024 | -247,914.13 |
| Sep 30, 2024 | -256,983.36 |
| Jun 30, 2024 | -243,376.59 |
| Mar 31, 2024 | -210,754.18 |
| Dec 31, 2023 | -74,239.85 |
| Sep 30, 2023 | -81,644.29 |
| Jun 30, 2023 | -72,957.93 |
| Mar 31, 2023 | -84,794.00 |
| Dec 31, 2022 | -177,523.04 |
| Sep 30, 2022 | -87,719.87 |
| Jun 30, 2022 | -290,239.42 |
| Mar 31, 2022 | -181,818.71 |
| Dec 31, 2021 | -891,153.37 |
| Sep 30, 2021 | 86,087.97 |